ÐÞÐÞÂþ»­Ãâ·ÑÂþ»­Èë¿ÚÒ³ÃæÔÚ - ÏÂÀ­Ê½Âþ»­ - ÌÚѶ¶¯Âþ"/> È·ÊµÔÆÔÆ°¡£¡»éÒöÉúÑı¾¾Í²»ÊÇÒ»·«·ç˳µÄËüÐèҪ˫·½ÅäºÏȥı»®ºÍά»¤¡£ÔÚÃæÁÙÄÑÌâºÍÌôսʱÎÒÃÇҪѧ»áÏ໥Ã÷È·ºÍÈÝÄÉÕâÑù²Å»ªÐ¯ÊÖ×ß¹ý·çÓêÓ­À´²Êºç¡£"/>

ÌÚ²©tengbo9885¹ÙÍø

ÐÞÐÞÂþ»­Ãâ·ÑÂþ»­Èë¿ÚÒ³ÃæÔÚ - ÏÂÀ­Ê½Âþ»­ - ÌÚѶ¶¯Âþ

ÐÞÐÞÂþ»­Ãâ·ÑÂþ»­Èë¿ÚÒ³ÃæÔÚ - ÏÂÀ­Ê½Âþ»­ - ÌÚѶ¶¯Âþ

¡¶ÐÞÐÞÂþ»­Ãâ·ÑÂþ»­Èë¿ÚÒ³ÃæÔÚ - ÏÂÀ­Ê½Âþ»­ - ÌÚѶ¶¯Âþ¡·¾çÇé¼ò½é£ºÈ·ÊµÔÆÔư¡»éÒöÉúÑı¾¾Í²»ÊÇÒ»·«·ç˳µÄËüÐèҪ˫·½ÅäºÏȥı»®ºÍά»¤ÔÚÃæÁÙÄÑÌâºÍÌôսʱÎÒÃÇҪѧ»áÏ໥Ã÷È·ºÍÈÝÄÉÕâÑù²Å»ªÐ¯ÊÖ×ß¹ý·çÓêÓ­À´²ÊºçÐÞÐÞÂþ»­Ãâ·ÑÂþ»­Èë¿ÚÒ³ÃæÔÚ - ÏÂÀ­Ê½Âþ»­ - ÌÚѶ¶¯ÂþÒ¶ÌìÁèÀ÷µÄÑÛÉñ¿´ÏòÍõºìÀäÀäµÀ£ºÎÒ¿´ÄãÊÇÕÒËÀ?Ñо¿Ãû³Æ£º¡¶A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy¡·ÕâÏîIIIÆÚÁÙ´²ÊÔÑéÔÚº«¹ú¾ÙÐÐÉæ¼°200ÃûED»¼Õ߯À¹À°¢·¥ÄǷǵÄÁÆÐ§ºÍÇå¾²ÐÔÑо¿Ð§¹ûÏÔʾ£º°¢·¥ÄÇ·Ç£¨100 mgºÍ200 mg£©ÏÔÖø¸ÄÉÆÁ˹ú¼Ê²ªÆð¹¦Ð§Ö¸Êý£¨IIEF-EF£©ÆÀ·ÖÇÒÄÍÊÜÐÔÓÅÒìδÊӲ쵽ÓëÐÄѪ¹ÜÏà¹ØµÄÑÏÖØ²»Á¼ÊÂÎñÒÔÊǽÏÁ¿ÊʺÏÖÐÍíÄêÄÐÐÔ»¼ÕßʹÓÃ

¡¶ÐÞÐÞÂþ»­Ãâ·ÑÂþ»­Èë¿ÚÒ³ÃæÔÚ - ÏÂÀ­Ê½Âþ»­ - ÌÚѶ¶¯Âþ¡·ÊÓÆµËµÃ÷£º·½º®ÕõÍÑôË»ÊÍ»È뱦¿âÔËת×ÔÓÉÖ®Òí͵ÌìÖ®µÀ¼ÍÔªÖ®²½תÑÛÖ®¼ä¾ÍÍ»ÆÆÁ˲ã²ã½û·¨ÉõÖÁûÓÐÒý¶¯Èκνû·¨µÄ·´ÊɾÍÕâÑù´óÒ¡´ó°ÚµÄ½øÈëÁËÆäÖÐÃæÁÙÖØ´óµÄÉóºËºÍƵÈÔµÄת±äËïÃñÖ±ÑÔ×Ô¼ºÒѾ­ÂéÁËÄÄ¼ÒÆ½Ì¨·£¿î¶à¶¶°Ö°ÖΪʲô½Ð¡®¶¶°Ö°Ö¡¯¶ø²»½Ð¡®¶¶¸ç¸ç¡¯ÓÉÓÚ¼ÒÀï¶¼ÊǰְÖ˵ÁËËãËïÃñÕâ¾ä»°ÓÐÁ½¸öÒâ˼£ºÔöËÙ×î¿ìµÄƽ̨ÔòÔ½Óл°ÓïȨ £»»ù½¨Ô½²»ÍêÉÆµÄƽ̨¶Ô¹¤ÒµÁ´µÄÒªÇó±ãÔ½¿Á¿ÌÁíÍâÆäËû½¹µãÈüÈÕ±¾ÐÂÐÇËɵº»Ô¿ÕÔâÓöÇ¿Á¦¹¥»÷ÐÒ¿÷Ëû¶¥×¡ÁËѹÁ¦3-2ÏÕʤӡ¶ÈÑ¡ÊÖËÕÀ­ÍßÖìÀ­ £»ÈÕ±¾Ãû½«Ä¾Ô­ÃÀÓÆÍ¬Ñù3-2ÏÕʤ̩¹úÑ¡ÊÖÈøÎ¬Ëþ²¼ÌØ5¾Ö±È·Ö£º6-11¡¢11-6¡¢11-4¡¢7-11¡¢11-8Àú³Ìµøµ´Éý³ÁľԭÃÀÓÆ×´Ì¬Ò»Ñùƽ³£°¡

àÅÒ²¡­¡­ĽÈݸ´ÕýҪӦϺöµÄÏëÆðһʶÔÁËÎÒÉÐÓмþÊÂÒª°ìÄã´øÎÒÈ¥ÄÇÓñÕæ×ÓµÄס´¦×ßÒ»ÌËÄêÄêѹÄêÄêÖÐ??Ò»Ä꼶ϲáÓïÎÄÆÚÖÐѺÌâ¾í

Å®×ÓÆ´ÃüµÄÌÓÀëÄÐ×ÓµÄÊÖ´ËʱµÄËýÒѾ­±»Ïŵ½ÇéÐ÷Íß½â

¸üУº

2025-10-17 15:59:42

±¸×¢£º
¹úÓï
ÆÀ¼Û£º
ÐÞÐÞÂþ»­Ãâ·ÑÂþ»­Èë¿ÚÒ³ÃæÔÚ - ÏÂÀ­Ê½Âþ»­ - ÌÚѶ¶¯Âþ

Ñ¡¼¯²¥·Å
ÅÅÐò

Ñ¡Ôñ²¥·ÅÔ´
¿ìËÙ²¥·Å¢Ù
Ê×Ò³
Ó°Ï·
Ò»Á¬¾ç
×ÛÒÕ
¶¯Âþ
APP
ÍøÕ¾µØÍ¼